[{"id":"57e7923b-444c-42db-bafc-dd83d0165277","acronym":"","url":"https://clinicaltrials.gov/study/NCT06482307","created_at":"2025-02-26T07:39:51.262Z","updated_at":"2025-02-26T07:39:51.262Z","phase":"Phase 1/2","brief_title":"Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET","source_id_and_acronym":"NCT06482307","lead_sponsor":"University Medical Center Groningen","biomarkers":" PARP1","pipe":"","alterations":" ","tags":["PARP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-01-01"},{"id":"04a57d4f-2959-452c-80a6-f0212d657b50","acronym":"","url":"https://clinicaltrials.gov/study/NCT04992013","created_at":"2021-08-05T13:53:09.751Z","updated_at":"2025-02-25T13:12:43.122Z","phase":"Phase 2","brief_title":"Niraparib in Tumors Metastatic to the CNS","source_id_and_acronym":"NCT04992013","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • BARD1 • NBN • RAD54L • XRCC2 • RAD54B • XRCC3","pipe":" | ","alterations":" HRD • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • BARD1 • NBN • RAD54L • XRCC2 • RAD54B • XRCC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/05/2022","start_date":" 04/05/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-12-12"},{"id":"0274e43f-cc0c-414e-9481-44dc1368c6ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT05515575","created_at":"2022-09-08T14:56:05.365Z","updated_at":"2025-02-25T13:13:08.083Z","phase":"Phase 2","brief_title":"A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA","source_id_and_acronym":"NCT05515575","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRCA1 • BRCA2 • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • CHEK1 • BARD1 • NBN • FANCF • FANCL • XRCC2 • ERCC4 • FANCI • FANCM • RAD52 • FANCD2 • FANCE • FANCG • RAD23B • RECQL4 • RPA1 • ABRAXAS1 • FANCC • RAD54B • SLX4","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • CHEK1 • BARD1 • NBN • FANCF • FANCL • XRCC2 • ERCC4 • FANCI • FANCM • RAD52 • FANCD2 • FANCE • FANCG • RAD23B • RECQL4 • RPA1 • ABRAXAS1 • FANCC • RAD54B • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 08/23/2022","start_date":" 08/23/2022","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-11-05"},{"id":"8cb4234f-c738-4083-b46f-8fc3430135ea","acronym":"ComPAKT","url":"https://clinicaltrials.gov/study/NCT02338622","created_at":"2021-01-17T17:26:12.811Z","updated_at":"2025-02-25T15:06:26.078Z","phase":"Phase 1","brief_title":"Trial of Olaparib in Combination with AZD5363 (ComPAKT)","source_id_and_acronym":"NCT02338622 - ComPAKT","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" BRCA1 • BRCA2 • PARP1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • PARP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Truqap (capivasertib)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 03/31/2014","start_date":" 03/31/2014","primary_txt":" Primary completion: 03/21/2016","primary_completion_date":" 03/21/2016","study_txt":" Completion: 03/21/2017","study_completion_date":" 03/21/2017","last_update_posted":"2024-09-26"},{"id":"269bcf7a-a222-4eb1-a733-a5c181aede05","acronym":"SURPASS-3","url":"https://clinicaltrials.gov/study/NCT05601752","created_at":"2022-11-05T15:14:24.529Z","updated_at":"2024-07-02T16:34:25.911Z","phase":"Phase 2","brief_title":"ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)","source_id_and_acronym":"NCT05601752 - SURPASS-3","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • BRCA • PARP1 • MAGEA4","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • BRCA • PARP1 • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 08/12/2026","primary_completion_date":" 08/12/2026","study_txt":" Completion: 08/12/2026","study_completion_date":" 08/12/2026","last_update_posted":"2024-06-14"},{"id":"04495210-d346-4ec0-a195-5cf3933896b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05038839","created_at":"2021-09-09T13:53:06.097Z","updated_at":"2024-07-02T16:35:09.419Z","phase":"Phase 1","brief_title":"Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors","source_id_and_acronym":"NCT05038839","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD50 • PARP1 • CHEK1 • EMSY","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • RAD50 mutation • CHEK1 mutation • CHEK1 expression","tags":["BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD50 • PARP1 • CHEK1 • EMSY"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • RAD50 mutation • CHEK1 mutation • CHEK1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Partruvix (pamiparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/09/2022","start_date":" 02/09/2022","primary_txt":" Primary completion: 06/03/2024","primary_completion_date":" 06/03/2024","study_txt":" Completion: 06/03/2024","study_completion_date":" 06/03/2024","last_update_posted":"2024-04-16"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"6802200c-eb8c-4b70-b41a-ca67c8450539","acronym":"","url":"https://clinicaltrials.gov/study/NCT05226663","created_at":"2022-02-12T17:47:36.827Z","updated_at":"2024-07-02T16:35:20.826Z","phase":"Phase 2","brief_title":"A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer","source_id_and_acronym":"NCT05226663","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PARP1","pipe":"","alterations":" ","tags":["PARP1"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/27/2023","start_date":" 02/27/2023","primary_txt":" Primary completion: 08/20/2026","primary_completion_date":" 08/20/2026","study_txt":" Completion: 08/20/2026","study_completion_date":" 08/20/2026","last_update_posted":"2024-02-06"},{"id":"2d096791-47a3-4df6-94ff-2b153a4bf104","acronym":"","url":"https://clinicaltrials.gov/study/NCT05128734","created_at":"2021-11-22T14:53:24.862Z","updated_at":"2024-07-02T16:35:21.430Z","phase":"Phase 2","brief_title":"Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)","source_id_and_acronym":"NCT05128734","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" HER-2 • ER • PGR • MGMT • BRCA • PARP1","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR • MGMT • BRCA • PARP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • temozolomide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-01-31"},{"id":"10d0956a-4ec0-46e8-936a-8b03707ecfe5","acronym":"NEO","url":"https://clinicaltrials.gov/study/NCT02489006","created_at":"2021-01-18T11:59:49.235Z","updated_at":"2025-02-25T15:06:39.652Z","phase":"Phase 2","brief_title":"A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer","source_id_and_acronym":"NCT02489006 - NEO","lead_sponsor":"University Health Network, Toronto","biomarkers":" BRCA1 • BRCA2 • PALB2 • RAD51B • BRIP1 • RAD51C • PARP1 • RAD51D • BARD1 • PPM1D • FANCM","pipe":" | ","alterations":" PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • PALB2 • RAD51B • BRIP1 • RAD51C • PARP1 • RAD51D • BARD1 • PPM1D • FANCM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 07/19/2016","start_date":" 07/19/2016","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-17"},{"id":"b5db6462-7119-4118-afe8-5aa585f0cacb","acronym":"IMMUNOPARP","url":"https://clinicaltrials.gov/study/NCT04675320","created_at":"2021-01-19T20:45:40.379Z","updated_at":"2024-07-02T16:35:26.865Z","phase":"","brief_title":"Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors","source_id_and_acronym":"NCT04675320 - IMMUNOPARP","lead_sponsor":"Centre Georges Francois Leclerc","biomarkers":" PARP1","pipe":"","alterations":" ","tags":["PARP1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/07/2020","start_date":" 07/07/2020","primary_txt":" Primary completion: 11/10/2022","primary_completion_date":" 11/10/2022","study_txt":" Completion: 11/10/2024","study_completion_date":" 11/10/2024","last_update_posted":"2023-12-07"},{"id":"5c9cf0d2-4000-4d44-8b92-7009c77ded0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04187833","created_at":"2021-01-18T14:26:39.615Z","updated_at":"2024-07-02T16:35:28.977Z","phase":"Phase 2","brief_title":"Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes","source_id_and_acronym":"NCT04187833","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" TMB • BRCA1 • BRCA2 • BAP1 • MLH1 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD50 • PARP1 • CHEK1 • NBN • HDAC2 • EMSY • ERCC3 • PRKDC • LIG3","pipe":"","alterations":" ","tags":["TMB • BRCA1 • BRCA2 • BAP1 • MLH1 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD50 • PARP1 • CHEK1 • NBN • HDAC2 • EMSY • ERCC3 • PRKDC • LIG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Talzenna (talazoparib)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 06/05/2020","start_date":" 06/05/2020","primary_txt":" Primary completion: 10/13/2023","primary_completion_date":" 10/13/2023","study_txt":" Completion: 10/13/2023","study_completion_date":" 10/13/2023","last_update_posted":"2023-11-16"},{"id":"3163b35c-7b87-40b8-a46f-d3b003617156","acronym":"COGNITION-GUIDE","url":"https://clinicaltrials.gov/study/NCT05332561","created_at":"2022-04-18T15:52:52.238Z","updated_at":"2025-02-25T12:28:45.270Z","phase":"Phase 2","brief_title":"Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)","source_id_and_acronym":"NCT05332561 - COGNITION-GUIDE","lead_sponsor":"German Cancer Research Center","biomarkers":" HER-2 • PD-L1 • PIK3CA • TMB • BRCA1 • BRCA2 • PARP1 • TACSTD2","pipe":" | ","alterations":" HER-2 positive • TMB-H • HR positive • MSI-H/dMMR • HER-2 negative • PIK3CA mutation • HER-2 exon 20 insertion • PALB2 mutation • HR positive + HER-2 negative • HER-2 exon 20 mutation","tags":["HER-2 • PD-L1 • PIK3CA • TMB • BRCA1 • BRCA2 • PARP1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • TMB-H • HR positive • MSI-H/dMMR • HER-2 negative • PIK3CA mutation • HER-2 exon 20 insertion • PALB2 mutation • HR positive + HER-2 negative • HER-2 exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Perjeta (pertuzumab) • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 06/29/2023","start_date":" 06/29/2023","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2023-07-06"},{"id":"83b910e1-0433-40bb-99bf-16eaee9ceb36","acronym":"OLALA","url":"https://clinicaltrials.gov/study/NCT02489058","created_at":"2021-01-18T11:59:50.872Z","updated_at":"2024-07-02T16:35:57.866Z","phase":"","brief_title":"A Study of Long-Term Responders on Olaparib","source_id_and_acronym":"NCT02489058 - OLALA","lead_sponsor":"University Health Network, Toronto","biomarkers":" HRD • BRCA • PARP1","pipe":" | ","alterations":" BRCA mutation","tags":["HRD • BRCA • PARP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 118","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 06/16/2021","primary_completion_date":" 06/16/2021","study_txt":" Completion: 08/31/2022","study_completion_date":" 08/31/2022","last_update_posted":"2023-01-10"},{"id":"419a98b5-d2bf-415b-9307-4fc2b382b434","acronym":"TOMAS","url":"https://clinicaltrials.gov/study/NCT02398058","created_at":"2021-04-14T18:53:45.928Z","updated_at":"2025-02-25T15:06:31.322Z","phase":"Phase 1","brief_title":"Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)","source_id_and_acronym":"NCT02398058 - TOMAS","lead_sponsor":"Italian Sarcoma Group","biomarkers":" BRCA1 • ERCC1 • ERCC2 • PARP1 • TP53BP1","pipe":"","alterations":" ","tags":["BRCA1 • ERCC1 • ERCC2 • PARP1 • TP53BP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Yondelis (trabectedin)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 07/20/2014","start_date":" 07/20/2014","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2021-04-14"},{"id":"d9db1684-d818-43fa-9529-2574c116f261","acronym":"Polen","url":"https://clinicaltrials.gov/study/NCT02506816","created_at":"2021-01-18T12:06:01.875Z","updated_at":"2025-02-25T15:06:43.322Z","phase":"","brief_title":"Preoperative Olaparib Endometrial Carcinoma Study (POLEN)","source_id_and_acronym":"NCT02506816 - Polen","lead_sponsor":"MedSIR","biomarkers":" PTEN • ARID1A • CCND1 • HIF1A • PARP1 • CASP3","pipe":" | ","alterations":" CCND1 expression • HIF1A expression","tags":["PTEN • ARID1A • CCND1 • HIF1A • PARP1 • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression • HIF1A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2020-11-30"},{"id":"c3fca746-2c87-4c39-b71e-3fcf60265718","acronym":"PHOENIX","url":"https://clinicaltrials.gov/study/NCT03740893","created_at":"2021-01-18T18:19:29.637Z","updated_at":"2025-02-25T15:08:06.285Z","phase":"Phase 2","brief_title":"PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer","source_id_and_acronym":"NCT03740893 - PHOENIX","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" HER-2 • ER • PGR • BRCA1 • CD8 • IFNG • LAG3 • BIRC5 • CXCL9 • PARP1 • TYMS • PTTG1 • RRM2 • CDC20 • CCNB1 • CEP55 • UBE2C","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • ER • PGR • BRCA1 • CD8 • IFNG • LAG3 • BIRC5 • CXCL9 • PARP1 • TYMS • PTTG1 • RRM2 • CDC20 • CCNB1 • CEP55 • UBE2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 10/15/2019","start_date":" 10/15/2019","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2020-02-21"},{"id":"01034882-ff09-4402-95a9-db47dc9eb1f2","acronym":"OPHELIA","url":"https://clinicaltrials.gov/study/NCT02882308","created_at":"2021-01-18T14:08:53.097Z","updated_at":"2025-02-25T15:07:14.796Z","phase":"Phase 2","brief_title":"Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.","source_id_and_acronym":"NCT02882308 - OPHELIA","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" PD-L1 • BRCA1 • BRCA2 • ERCC1 • ERCC2 • RAD51C • GSTP1 • PARP1 • XRCC1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • BRCA1 • BRCA2 • ERCC1 • ERCC2 • RAD51C • GSTP1 • PARP1 • XRCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin • Imfinzi (durvalumab)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 10/20/2016","start_date":" 10/20/2016","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 01/10/2020","study_completion_date":" 01/10/2020","last_update_posted":"2020-02-07"},{"id":"584ade20-3424-478f-a8af-d61ca6c3ee46","acronym":"","url":"https://clinicaltrials.gov/study/NCT01495351","created_at":"2023-10-15T04:12:52.216Z","updated_at":"2024-07-02T16:37:17.612Z","phase":"Phase 1","brief_title":"Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma","source_id_and_acronym":"NCT01495351","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" PARP1","pipe":"","alterations":" ","tags":["PARP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • veliparib (ABT-888) • dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 02/01/2015","primary_completion_date":" 02/01/2015","study_txt":" Completion: 02/10/2015","study_completion_date":" 02/10/2015","last_update_posted":"2017-09-25"},{"id":"ba24ef7d-1f4f-49ea-9992-e392030963e9","acronym":"POLA","url":"https://clinicaltrials.gov/study/NCT02684318","created_at":"2021-01-19T11:44:36.764Z","updated_at":"2025-02-25T14:57:32.272Z","phase":"Phase 1/2","brief_title":"Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors","source_id_and_acronym":"NCT02684318 - POLA","lead_sponsor":"Poveda, Andrés, M.D.","biomarkers":" BRCA1 • PTEN • PARP1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD + BRCA1 mutation","tags":["BRCA1 • PTEN • PARP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD + BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Zepzelca (lurbinectedin)"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 07/01/2019","primary_completion_date":" 07/01/2019","study_txt":" Completion: 10/01/2019","study_completion_date":" 10/01/2019","last_update_posted":"2017-06-22"}]